| Literature DB >> 34349911 |
Daniel J Leonard1, Francis Zieleniewski1, Isabelle Wellhöfer1, Emily G Baker1,2,3, John W Ward1, Derek N Woolfson1,2,3, Jonathan Clayden1.
Abstract
Quaternary amino acids are important tools for the modification and stabilisation of peptide secondary structures. Here we describe a practical and scalable synthesis applicable to quaternary alpha-arylated amino acids (Q4As), and the development of solid-phase synthesis conditions for their incorporation into peptides. Monomeric and dimeric α-helical peptides are synthesised with varying degrees of Q4A substitution and their structures examined using biophysical methods. Both enantiomers of the Q4As are tolerated in folded monomeric and oligomeric α-helical peptides, with the (R)-enantiomer slightly more so than the (S). This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 34349911 PMCID: PMC8278958 DOI: 10.1039/d1sc01378e
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Scheme 1Synthetic pathways from l-alanine to Fmoc-protected S and R-(α-4-bromophenyl)alanine 4a by way of N-chloroformylimidazolidinone 2a or N′-bromophenyl imidazolinyl urea 6a. The sequence shown by the orange arrows starting from 1 constitutes a general S-selective route to quaternary alpha-arylated amino acids (Q4As) S-4, whereas the sequence shown by the green arrows constitutes an R-selective route to Q4As R-4. KHMDS = potassium hexamethyldisilazide.
Synthesis of Fmoc-protected Q4As via imidazolidinones 3
| R= | X= |
| ( |
|---|---|---|---|
| H | 4-Br |
|
|
| H | 3-Br |
|
|
| H | 3-CN |
| |
| H | 3,5-F2 |
|
|
| H | 3,5-Cl2 |
| |
| Ph | 4-Cl |
|
|
| Ph | 4-Me |
|
|
| Ph | 3-Br |
|
|
| 4-BnOC6H4 | 4-Me |
| |
| 4-BnOC6H4 | 3-F, 4-Br |
|
Designed peptides and summary of biophysical dataa
|
|
Letters are standard one-letter amino acid codes, plus B/b: S/R-α-(4-bromophenyl)alanine; Φ/ϕ: l/d-phenylglycine; U: α-aminoisobutyric acid (Aib).
Fig. 1Helical-wheel representations of CC-Mono (A) and CC-Di (B). (C) CD spectra of peptides 8–14. (D) CD spectra of peptides 15–17. (E) Variable temperature CD measurements for peptides 15–17 monitoring MRE222 from 5 to 95 °C. All CD measurements were carried out with 50 μM peptide in phosphate-buffered saline (PBS, pH 7.4). (F–H) Sedimentation equilibrium profiles for peptides 15–17 respectively. Top: SE data (circles) fitted to a single-ideal species model (black lines). Bottom: residuals for the above fits. SE measurements were carried out at 20 °C in PBS, pH 7.4 at 37 μM for peptide 15 and 75 μM for peptides 16 & 17.